Exelixis Current Deferred Revenue from 2010 to 2026
| EXEL Stock | USD 43.92 1.22 2.86% |
Current Deferred Revenue | First Reported 2000-12-31 | Previous Quarter 2.9 M | Current Value 2.2 M | Quarterly Volatility 32.1 M |
Check Exelixis financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Exelixis' main balance sheet or income statement drivers, such as Interest Expense of 64.9 M, Total Revenue of 2.4 B or Gross Profit of 2.3 B, as well as many indicators such as Price To Sales Ratio of 4.17, Dividend Yield of 0.0 or PTB Ratio of 3.37. Exelixis financial statements analysis is a perfect complement when working with Exelixis Valuation or Volatility modules.
Exelixis | Current Deferred Revenue | Build AI portfolio with Exelixis Stock |
Historical Current Deferred Revenue data for Exelixis serves as a key indicator of operational performance and financial stability. Tracking changes in this metric over time helps investors spot emerging trends before they become obvious, providing an edge in assessing whether Exelixis represents a compelling investment opportunity.
Latest Exelixis' Current Deferred Revenue Growth Pattern
Below is the plot of the Current Deferred Revenue of Exelixis over the last few years. It is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. Exelixis' Current Deferred Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Exelixis' overall financial position and show how it may be relating to other accounts over time.
| Current Deferred Revenue | 10 Years Trend |
|
Current Deferred Revenue |
| Timeline |
Exelixis Current Deferred Revenue Regression Statistics
| Arithmetic Mean | 11,722,761 | |
| Geometric Mean | 7,234,351 | |
| Coefficient Of Variation | 98.25 | |
| Mean Deviation | 8,897,608 | |
| Median | 7,488,000 | |
| Standard Deviation | 11,517,762 | |
| Sample Variance | 132.7T | |
| Range | 40.5M | |
| R-Value | (0.53) | |
| Mean Square Error | 102.1T | |
| R-Squared | 0.28 | |
| Significance | 0.03 | |
| Slope | (1,204,298) | |
| Total Sum of Squares | 2122.5T |
Exelixis Current Deferred Revenue History
About Exelixis Financial Statements
Exelixis investors utilize fundamental indicators, such as Current Deferred Revenue, to predict how Exelixis Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 2.5 M | 2.3 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out the analysis of Exelixis Correlation against competitors. For more information on how to buy Exelixis Stock please use our How to buy in Exelixis Stock guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Exelixis. Projected growth potential of Exelixis fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Exelixis assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth 0.842 | Earnings Share 2.78 | Revenue Per Share | Quarterly Revenue Growth 0.056 | Return On Assets |
Investors evaluate Exelixis using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Exelixis' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Exelixis' market price to deviate significantly from intrinsic value.
It's important to distinguish between Exelixis' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Exelixis should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Exelixis' market price signifies the transaction level at which participants voluntarily complete trades.